US Earnings Financial Results SEC Filings — March 18, 2026

18-03-2026

For the year ended December 31, 2025, Unknown Company's total investment income declined 5.5% YoY to $91,000 from $96,337, while total expenses increased 5.7% to $48,437, resulting in net investment income dropping 15.8% to $42,543. The weighted average current yield for the total portfolio fell to 9.9% (amortized cost basis) from 11.2% YoY and 10.7% (fair value basis) from 11.9%, amid total investments at $4.3M amortized cost and $4.2M fair value as of year-end. However, net realized losses improved to ($3,681) from ($4,996) and unrealized depreciation narrowed to ($5,740) from ($6,434), leading to net increase in net assets from operations of $33,122, down 15.3% YoY.

• ·JPM Facility and CIBC Facility interest expenses reduced to $0 in 2025 from $17,729 and $1,715 respectively in 2024.
• ·SMBC Facility interest expenses increased to $2,512 from $1,814 YoY, with weighted average outstanding debt down to $37,744 from $62,794.
• ·VCC CLO interest expenses rose sharply to $23,411 from $2,386 YoY on stable $377,500 debt balance.
• ·Base management fees up 11.2% YoY to $6,350, but income-based incentive fees down 15.3% to $4,732.
• ·Interest expenses (total) increased to $30,800 from $28,495 YoY.

18-03-2026

18-03-2026

18-03-2026

Natural Resource Holdings, Inc. (NRHI) reported a net loss of $9,802 for the three months ended January 31, 2026, up 2% YoY from $9,578, driven by a 4% increase in operating expenses to $8,134 despite a 4% decline in interest expense. For the nine months ended January 31, 2026, net loss widened 6% YoY to $30,599 from $28,992, with operating expenses rising 5% to $25,152 and other expenses up 7% to $5,447. Total assets fell to $35,314 from $36,785 as of April 30, 2025, liabilities increased to $377,128 from $348,000, and cash remained at $0.

• ·Cash and cash equivalents remained at $0 throughout periods.
• ·No revenue reported; zero total current assets.
• ·Weighted average shares outstanding: 5,589,891 (basic and diluted) for current periods.
• ·Mining property rights net: $35,314 (Jan 31, 2026) after $1,471 amortization.

18-03-2026

TSS, Inc. reported total revenues of $245.7M for FY 2025, up 66% YoY from $148.1M in FY 2024, driven by strong growth in Procurement (+68% to $197.5M) and Systems Integration (+78% to $40.3M); however, Facilities Management revenues declined 1% YoY to $7.9M from $8.0M. Gross profit in Procurement more than doubled to $15.2M (+94% YoY) with margins expanding to 7.7% from 6.7%, while the company invested over $40M in its Georgetown, Texas integration facility to support AI-driven demand. Significant deferred revenue backlog includes $115.1M in long-term performance obligations.

• ·Repurchased 988 shares in December 2025 at average price of $9.46 per share.
• ·Revenues recognized at a point in time: $227.6M in FY 2025 (vs $139.6M in FY 2024).
• ·Revenues recognized over time: $18.1M in FY 2025 (vs $8.6M in FY 2024).

18-03-2026

Bob's Discount Furniture reported FY 2025 net revenues of $2.37B, up 16.8% YoY from $2.03B, with comparable sales growth of 7.7% (vs -3.4% prior year), net income of $122M up 38.4% YoY, and Adjusted EBITDA of $241M up 24.1% to 10.2% of revenues; the company opened 20 new stores, reaching 209 total. However, gross margin compressed to 45.7% from 46.8% amid 19.2% higher cost of sales, operating income margin improved to 7.1% but prior year (FY2024) was flat at 5.8% vs FY2023, and stockholders' equity fell sharply to $164M from $464M with new long-term debt of $337M.

• ·Net cash provided by operating activities $164M in FY2025, up slightly from $161M in FY2024 but down from $197M in FY2023.
• ·Cash and cash equivalents declined to $53M from $81M YoY.
• ·Inventories increased to $350M from $304M YoY.
• ·Total liabilities rose to $1.65B from $1.16B, driven by $337M long-term debt.
• ·Restricted cash $9M as of Dec 28, 2025.

18-03-2026

Vyome Holdings, Inc reported revenue growth of 24% YoY to $319,714 and gross profit up 12% to $218,771 for the year ended December 31, 2025. However, operating expenses ballooned to $10.7M from $1.2M primarily due to $7.7M in transactional fees, resulting in a net loss of $10.5M versus $1.4M in 2024. The balance sheet improved significantly with total assets at $6.5M (up 370% YoY), cash at $5.0M (up 4,789%), liabilities down 53% to $2.7M, and stockholders' equity turning positive at $3.8M from a $4.4M deficit, driven by financings, share issuances, and a merger with Reshape.

• ·Loss per share improved to ($4.86) from ($6,001.39) due to increased shares outstanding (weighted avg 2,161,342 vs 241).
• ·Net cash used in operating activities increased to $3.7M from $0.6M.
• ·Net cash provided by financing activities $8.7M in 2025 vs $0.7M in 2024, including $1.3M ATM and $6.6M concurrent financing.

18-03-2026

dMY Squared Technology Group, Inc. reported a sharply widened net loss of $17.8M for the year ended December 31, 2025, compared to $0.8M in 2024, driven by a $14.3M unfavorable change in fair value of derivative warrant liabilities (vs. $0.5M prior year) and general and administrative expenses surging 310% YoY to $4.5M. While cash and investments held in the Trust Account increased 6.7% YoY to $27.3M, operating cash plummeted nearly 100% to just $78 and total liabilities ballooned to $27.2M (up 268% YoY), primarily from warrant liabilities reaching $15.7M. Shareholders' deficit deteriorated to $(27.0M) from $(6.8M), reflecting remeasurements and conversions.

• ·Class A common stock EPS basic declined to $(4.55) from $(0.21) YoY.
• ·Accrued expenses rose to $4.2M from $0.8M as of Dec 31, 2025.
• ·Convertible notes - related parties increased to $1.2M from $0.6M.
• ·Advances from related parties jumped to $2.4M from $0.4M.

18-03-2026

Total investments grew approximately 71% YoY to $357M as of December 31, 2025 from $209M, with the number of portfolio companies increasing to 64 from 54 and total investment income rising 58% to $28.8M, contributing to a 45% increase in net increase in net assets from operations to $21.8M. Net assets expanded 68% to $205M. However, weighted average yield on debt investments declined to 9.88% from 11.11% YoY, net realized losses widened to $(0.9M) from $(0.1M), and Class I NAV per share dipped slightly to $24.87 from $24.93.

• ·Credit facility borrowings increased to $166M from $94M YoY.
• ·Net realized gain/loss was a loss of $0.9M in 2025 vs $0.1M loss in 2024.
• ·All debt investments bear floating rates (100%) in both 2025 and 2024.
• ·Interest expense rose to $7.2M from $3.3M YoY.

18-03-2026

Protalix BioTherapeutics reported total revenue of $52.7M for the year ended December 31, 2025, down 1.2% YoY from $53.4M in 2024 (which was down 18.5% from $65.5M in 2023), driven by a sharp prior drop in license and R&D revenues and a slight decline in goods sales despite growth from Pfizer. Revenues from selling goods fell 2.2% YoY to $51.8M, with Chiesi down $6.8M while Fiocruz remained flat; the company swung to an operating loss of $5.5M and net loss of $6.6M from profits of $3.9M and $2.9M in 2024. Total assets increased to $82.3M from $73.4M, supported by higher inventories and equity rising to $48.2M amid share issuances.

• ·Basic EPS (loss) per share: ($0.08) in 2025 vs $0.04 profit in 2024.
• ·Cash and cash equivalents declined to $14.7M from $19.8M YoY.
• ·Inventories increased to $25.7M from $21.2M.
• ·Weighted average basic shares: 78.5M in 2025.

18-03-2026

Golden Growers Cooperative reported flat net income of $6.1M for 2025, up slightly 0.3% YoY from $6.0M, driven by modest 0.5% YoY corn revenue growth to $62.3M and 3.6% YoY increase in net income from ProGold LLC to $6.5M; however, corn expenses rose 0.4% YoY, other income declined 36.5% to $0.3M, G&A expenses increased 10.2%, and total assets fell to $20.3M from $24.9M amid higher member distributions of $10.7M (up 38% YoY). Income from operations grew 3.2% YoY to $5.8M, but members' equity decreased to $20.1M due to distributions exceeding net income. All directors are confirmed independent per defined criteria.

• ·Net cash used in operating activities remained flat at ($0.4M) for both 2025 and 2024.
• ·Cash and cash equivalents declined to $1.2M as of Dec 31 2025 from $1.3M.
• ·Short-term investments decreased to $4.6M from $7.3M; long-term investments fell to $0.05M from $0.4M.
• ·All directors are independent based on defined criteria, including thresholds like $120,000 compensation and $1M payment limits.
• ·EPS basic and fully diluted stable at $0.39 for both years.

18-03-2026

Pacific Health Care Organization Inc (PFHO) reported total revenues of $6.7M for the year ended December 31, 2025, up 11% YoY from $6.1M, driven by robust growth in medical case management (+42% to $2.2M) and utilization review (+5% to $2.2M), while HCO declined 2%, medical bill review fell 4%, and other revenues dropped 70%. Net income rose 57% to $1.4M from $0.9M, bolstered by 17% higher operating income and $0.4M in other income (none prior year), though total expenses increased 10% due to jumps in professional fees (+55%) and data maintenance (+131%). Cash from operations improved to $1.2M from $0.7M, with total assets growing to $13.5M.

• ·Basic and diluted EPS: $0.11 (2025) vs $0.07 (2024)
• ·Total expenses: $5.7M (2025) vs $5.2M (2024), +10%
• ·Investments: $10.0M (Dec 31 2025) vs $9.0M (2024)
• ·Current liabilities decreased to $0.4M from $0.7M
• ·Net cash used in investing: ($1.0M) vs ($1.1M)
• ·Retained earnings: $12.6M (2025) vs $11.3M (2024)

18-03-2026

ProKidney Corp. reported FY 2025 revenue of $893 thousand, up over 1,075% YoY from $76 thousand in FY 2024, driven by initial commercialization efforts. Operating expenses declined 9.7% YoY to $165.9 million, resulting in a smaller operating loss of $165.0 million; however, net loss available to Class A common stockholders increased 12.7% YoY to $69.0 million from $61.2 million due to changes in noncontrolling interest allocation. Net cash increased $9.4 million in FY 2025, down from $38.5 million in FY 2024, with operating cash use improving slightly to $120.1 million.

• ·Consolidated financial statements cover years ended December 31, 2025, 2024, and 2023.
• ·Independent auditor: PCAOB ID No. 42.
• ·Net cash from investing activities: $104.0M in FY 2025 vs $20.4M in FY 2024.

18-03-2026

Energy Vault Holdings, Inc. reported revenue of $203.7M for 2025, up 341% YoY from $46.2M, driven by $196.2M in energy storage products sales (up 340% YoY), with gross profit surging to $48.0M from $6.2M. Net loss narrowed to $103.7M from $135.8M, and total cash rose to $103.4M from $30.1M, supported by $123.1M in financing inflows. However, operating loss remained at $74.4M, G&A expenses increased 29% YoY to $81.2M, sales and marketing declined 14% YoY, and adjusted EBITDA loss widened slightly to $21.2M from $58.0M.

• ·Net cash used in operating activities improved to $5.6M from $55.9M YoY.
• ·Restricted cash increased to $45.2M from $3.0M, primarily related to customer projects ($33.0M).
• ·Stock-based compensation expense $36.7M in 2025 vs $38.7M in 2024.
• ·Provision for credit losses declined to $9.4M from $30.0M.

18-03-2026

HeartFlow, Inc. reported FY2025 revenue of $176M, up 40% YoY from $126M in 2024, with revenue cases surging 53% from Q4 2024 (37,805) to Q4 2025 (57,776) and gross profit rising 43% to $135M. However, net loss expanded 21% to $117M due to 28% higher total operating expenses ($199M), including 49% YoY increase in R&D ($65M) and 20% in SG&A ($134M), while loss from operations worsened slightly by 5%. The company completed an IPO, raising $332M in net proceeds, converting all redeemable preferred stock and convertible notes to common stock, eliminating $136M term loan and $21M warrant liability, and flipping stockholders' equity to positive $301M from a $859M deficit.

• ·Net cash used in operating activities improved to $54M in FY2025 from $69M in FY2024 and $76M in FY2023.
• ·Accounts receivable increased to $29.3M at Dec 31, 2025 from $24.6M at Dec 31, 2024.
• ·Term loan fully repaid ($136M at Dec 31, 2024 reduced to $0).
• ·Short-term and long-term investments totaled $235M at Dec 31, 2025 (none in 2024).

18-03-2026

Accelerant Holdings reported total revenues of $912.9M in 2025, up 51.5% YoY from $602.6M, driven by 35% growth in exchange written premium to $4.19B and membership expansion to 280 (+29% YoY), alongside strong adjusted EBITDA of $281.8M (up 149% YoY, 31% margin). However, the company swung to a significant net loss of $1.35B from 2024 profit of $22.9M, primarily due to $1.38B profits interest distribution expenses and higher G&A at $400.4M, while net revenue retention declined to 126% from 153%.

• ·Gross loss ratio improved slightly to 51.3% in 2025 from 54.3% in 2024.
• ·Accelerant direct written premium share decreased to 70% in 2025 from 84% in 2024.
• ·Deferred excess ceding commissions balance increased to $232.5M as of Dec 31, 2025 from $193.0M.
• ·Net loss ratio improved to 68.4% in 2025 from 73.8% in 2024.

18-03-2026

United Bancorp, Inc. (UBCP), a bank holding company for Unified Bank, filed its 10-K annual report for the fiscal year ended December 31, 2025, on March 18, 2026. The company reported 5,756,852 common shares outstanding as of March 11, 2026, with an aggregate market value of non-affiliate shares of $66.1M as of June 30, 2025. It operates 18 branches serving Ohio and West Virginia markets, ranking fourth in deposit market share in Belmont County.

• ·Headquartered in Martins Ferry, Ohio; incorporated July 8, 1983.
• ·Serves Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties in Ohio, and Ohio and Marshall counties in West Virginia.
• ·Annual shareholders meeting scheduled for April 22, 2026.
• ·Classified as a smaller reporting company and non-accelerated filer.

18-03-2026

Best Buy's FY2026 revenue rose slightly 0.4% YoY to $41.691B from $41.528B, with comparable sales up 0.5% and net earnings increasing to $1.069B (Diluted EPS $5.04, up from $4.28). However, gross profit dipped to $9.373B, total stores declined to 1,068 from 1,117, and segments like Consumer Electronics (-5.4% comp sales) and Appliances (-8.9%) showed declines, while Domestic revenue was nearly flat at 0.1% growth. Adjusted operating income margin improved modestly to 4.3%, but remained below 2024 levels.

• ·Restructuring charges: $190M in FY2026
• ·Goodwill and intangible asset impairments: $171M in FY2026 (down from $475M in FY2025)
• ·Online revenue as % of Domestic segment revenue: 34.4% in FY2026 (up from 34.0%)
• ·Cash from operating activities down 6.5% YoY to $1.962B
• ·Adjusted diluted EPS: $6.43 in FY2026 (up from $6.37)

18-03-2026

Envela Corp reported consolidated sales growth of 33.6% YoY to $241.0M for the year ended December 31, 2025, driven by strong 47.7% increase in Consumer segment sales to $192.7M, while Commercial segment sales declined 3.2% to $48.3M. Gross margin dollars rose to $53.9M but the margin percentage compressed to 22.4% from 24.6% due to higher COGS as a percentage of sales (77.6% vs. 75.4%); however, operating income improved significantly to $18.1M (7.5% of sales) from $8.2M, resulting in net income of $14.6M (up from $6.8M).

• ·EPS increased 115.4% YoY to $0.56 from $0.26.
• ·Consolidated SG&A expenses decreased slightly to $33.9M (14.1% of sales) from $34.6M (19.2% of sales).
• ·Commercial COGS declined 19.4% to $17.3M, improving to 35.8% of Commercial sales from 43.0%.
• ·Income tax expense rose 107.1% to $4.1M.

18-03-2026

Usio, Inc. reported total revenues of $85.4M for the year ended December 31, 2025, up 3% YoY from $82.9M, driven by strong 33% growth in ACH and complementary services to $22.2M, with credit card revenue up 3% to $30.0M. However, prepaid card services revenue declined 22% to $11.0M, output solutions remained flat at 0% growth ($20.6M), operating loss widened to $2.4M from $1.5M, and adjusted EBITDA fell 54% to $1.3M (1.6% margin) from $2.9M (3.5% margin). The filing highlights ongoing business risks, including history of losses, cybersecurity threats, key personnel dependence, and potential need for additional financing.

• ·Filing date: March 18, 2026
• ·Audited by WithumSmith+Brown, P.C. and Pannell Kerr Forster of Texas, P.C.
• ·Depreciation and amortization: $1.95M in 2025 vs $2.26M in 2024
• ·Non-cash stock-based compensation: $1.74M in 2025 vs $2.09M in 2024

18-03-2026

For FY 2025, ONE STOP SYSTEMS, INC. reported revenue of $32.2M, up 31% YoY from $24.6M, driven by 46% growth in product revenue to $30.5M, though customer-funded development revenue declined 53% to $1.7M. Gross profit surged to $16.0M (49.6% margin) from $0.6M (2.5% margin), narrowing the continuing operations loss to $3.1M from $15.2M and operating loss to $3.4M from $15.7M; net income turned positive at $5.1M versus a $13.6M loss, boosted by $8.2M from discontinued operations. However, operating cash flow from continuing activities worsened to -$6.6M used from -$2.6M, and total operating expenses rose 19% to $19.4M.

• ·Adjusted EBITDA from continuing operations improved to -$0.8M from -$12.8M.
• ·Non-GAAP net loss from continuing operations narrowed to -$1.3M or -$0.06 per share from -$13.3M or -$0.64 per share.
• ·Gain on sale from discontinued operations: -$6.7M (adjustment).
• ·Net cash provided by discontinued operations: $17.9M in FY2025 vs $1.4M in FY2024.
• ·Total Adjusted EBITDA: $1.8M in FY2025 vs -$10.3M in FY2024.

18-03-2026

Home Depot's FY2025 net sales rose 3.2% YoY to $164.7B from $159.5B, supported by a 1.4% increase in average ticket to $90.56 despite a 2.2% drop in customer transactions to 1,601.5 million. However, comparable sales grew only 0.3% (flat), operating income declined 2.9% to $20.9B, net earnings fell 4.3% to $14.2B, and diluted EPS decreased 4.6% to $14.23. ROIC also dropped sharply to 25.7% from 31.3%.

• ·Total stockholders’ equity increased to $12.8B from $6.6B YoY.
• ·Short-term debt rose sharply to $4.5B from $0.3B.
• ·Merchandise inventories grew to $25.8B from $23.5B.
• ·FY2024 included 53 weeks vs 52 weeks in FY2025.

18-03-2026

Hyperfine, Inc. reported total sales of $13.6M for the year ended December 31, 2025, up 5.2% YoY from $12.9M, driven by 9.1% growth in device sales to $11.4M, though service sales declined 11.3% to $2.2M. Gross profit rose 14.6% to $6.8M as total cost of sales fell 2.7%, and operating expenses decreased 10.7% to $43.8M, narrowing the net loss to $35.6M from $40.7M (12.6% improvement). However, interest income dropped sharply 58.9% to $1.0M, and sales & marketing expenses increased 11.1% to $10.1M.

• ·Net cash used in operating activities improved to $(28.0M) from $(38.8M) YoY.
• ·Net cash provided by financing activities was $27.5M in 2025 vs $1.0M in 2024.
• ·Independent auditor: GRANT THORNTON LLP (PCAOB ID 248).

18-03-2026

Avidbank Holdings, Inc. filed its 10-K annual report on March 18, 2026, emphasizing a strategic focus on expanding its deposit base via commercial relationships, treasury management services, and specialized deposit products to enhance liquidity and non-interest income. The filing provides explanations of regulatory capital metrics like CET1 ratio and discloses extensive risk factors, including geographic concentration in the California Bay Area, volatile nonperforming assets, dependency on large depositors and borrowers, liquidity risks, and regulatory restrictions on dividends. In Q4 2025, 4,810 shares of common stock were surrendered by employees for tax withholding obligations related to restricted stock vesting at an average price of $25.12 per share, with none purchased under a public repurchase program and 282,433 shares remaining authorized.

• ·Share surrenders not part of publicly announced repurchase program.
• ·CET1 Risk-Based Capital Ratio excludes accumulated other comprehensive income per one-time election.

18-03-2026

Ovid Therapeutics Inc. reported total revenue of $7.3M for the year ended December 31, 2025, a sharp increase from $0.6M in 2024 driven by license and other revenue. Operating expenses declined 20% to $49.7M, narrowing the net loss to $17.4M from $26.4M and improving loss from operations to $42.4M from $61.9M. However, cash used in operating activities was $38.3M (improved from $56.0M but still significant), investing activities used $49.9M net cash (vs. provided $54.6M prior), and cash equivalents dropped to $13.2M from $26.3M amid a $13.1M net decrease.

• ·Common shares issued and outstanding increased to 130.2M from 71.0M due to conversions of Series A and B preferred stock.
• ·Proceeds from private placement financing, net of costs: $75.1M in 2025.
• ·Issuance of Series A warrants: $13.8M to additional paid-in capital; Series B warrants: $17.7M.
• ·Stock-based compensation expense declined to $4.8M from $6.3M.
• ·No provision for income taxes in either year.

18-03-2026

Gold Resource Corp ended 2025 with cash and equivalents of $25.0M, up $23.4M YoY, and working capital of $32.0M, a 1,424% increase from $2.1M, driven by debt/equity issuance, improved production, and higher metal prices. Net sales rose 52% YoY to $99.8M with gold equivalent ounces sold up 24% to 23,125 oz and mine gross profit of $26.8M versus a $20.5M loss in 2024; however, the company reported a net loss of $6.5M (improved from $56.5M) amid sharp declines in gold production (-42% to 4,944 oz) and base metals like copper (-63% to 240 tonnes), lead (-53% to 1,014 tonnes), and zinc (-53% to 2,940 tonnes).

• ·Silver sales increased to $66.1M in 2025 from $23.1M in 2024, while gold sales declined to $17.8M from $19.8M.
• ·Average realized gold price rose to $3,657/oz from $2,354/oz; silver to $45.48/oz from $28.75/oz.
• ·Treatment and refining charges decreased to $3.4M from $5.7M.

18-03-2026

Hills Bancorporation reported total assets of $4.57B as of December 31, 2025, up 4.5% YoY from $4.37B, with net loans growing 2.1% to $3.46B and net income surging 27.1% to $60.5M (EPS $6.81). Net interest income rose sharply 29.0% to $153.7M, driven by higher loan yields (5.66% vs 5.30%) and improved net interest margin (3.45% vs 2.78%), while interest expense declined 4.6% to $83.6M. However, time deposits fell 5.1% to $870.3M, interest-bearing demand deposits decreased 1.9% to $901.2M, and reliance on borrowings increased with other short-term borrowings at $297.7M (up from $332.8M prior but elevated vs 2023).

• ·Noninterest-bearing demand deposits increased 2.3% YoY to $577.6M.
• ·Savings deposits grew 11.2% YoY to $992.1M.
• ·Other short-term borrowings $297.7M (down 10.5% YoY from $332.8M but up significantly from 2023 $214.3M).
• ·FHLB borrowings $344.95M (up 80.3% YoY from $191.35M).
• ·Taxable securities up 9.3% YoY to $605.7M.
• ·Redeemable common stock held by ESOP $52.7M.

18-03-2026

TEN Holdings, Inc. reported FY2025 total revenue of $3.1M, down 11.4% YoY from $3.5M, with virtual/hybrid events declining 15.0% to $2.7M while physical events grew 28.8% to $0.4M. Net loss widened dramatically to $19.5M from $2.97M, driven by SG&A expenses surging 183.4% to $15.3M and total operating expenses up 184.4%; cash and equivalents ended at $1.6M after $12.5M in financing inflows primarily from share issuance.

• ·Net cash used in operating activities worsened to $(10.1M) from $(2.5M) YoY.
• ·Stock-based compensation expense of $4.9M and impairment loss on intangible assets of $4.2M in FY2025.
• ·Related party short-term loans: V-Cube, Inc. $0.5M outstanding (peak $4.1M); Naoaki Mashita $0.1M (peak $0.5M); Wizlearn $1.7M (peak $1.8M); PAVE $2.3M (peak $2.3M).

18-03-2026

Dogwood Therapeutics, Inc. reported total operating expenses of $28.0M for the year ended December 31, 2025, up 129% YoY from $12.2M in 2024, primarily due to a 519% surge in R&D expenses to $21.9M, while G&A expenses declined 30% to $6.1M. The company posted a pre-tax loss of $34.0M, more than double the $12.4M loss in 2024, including a $6.1M loss on debt conversion with a related party. Net cash decreased by $8.3M in 2025 versus an increase of $11.7M in 2024, with operating cash use rising 78% to $15.6M.

• ·Filing date: March 18, 2026
• ·Cash provided by investing activities: $0 in 2025 vs $3.8M in 2024
• ·Cash provided by financing activities: $7.3M in 2025 vs $16.7M in 2024
• ·Discusses risks related to commercialization, including financial, regulatory, and compliance risks under U.S. Foreign Corrupt Practices Act and state laws

18-03-2026

4D Molecular Therapeutics' collaboration and license revenue surged to $85.2M in 2025 from $37K in 2024, significantly narrowing net loss to $140.1M (-13% YoY) and improving loss from operations by 15% to $159.5M despite total operating expenses rising 30% to $244.8M, driven by 38% higher R&D spend. However, cash and equivalents declined sharply to $60.2M from $149.3M, with net cash used in operations improving modestly to $109.1M but still reflecting high burn, and other income fell 28% YoY.

• ·Weighted-average shares outstanding increased to 57.9M in 2025 from 53.9M in 2024; net loss per share improved to $(2.42) from $(2.98).
• ·Financing activities provided $113.0M in 2025 (down from $337.3M in 2024), including $93.5M from underwritten offering and $9.7M from ATM.
• ·Stock-based compensation expense declined to $22.0M in 2025 from $26.1M in 2024.

18-03-2026

AEye, Inc. reported FY2025 revenue of $0.233M, up 15% YoY from $0.202M, with gross loss narrowing 44% to $0.321M due to a 29% reduction in cost of revenue. Operating expenses fell 11% to $31.41M, driven by 15% and 18% declines in R&D and G&A, respectively, resulting in an 11% smaller operating loss and 4% reduced net loss of $33.96M; however, sales and marketing expenses surged 362% to $2.55M amid ongoing deep losses. Strong financing activities provided $91.7M, boosting cash and equivalents to $43.4M from $10.3M and total assets to $90.9M.

• ·Net cash used in operating activities increased slightly to $27.8M in FY2025 from $26.6M.
• ·Net cash used in investing activities was $30.8M in FY2025, compared to provided by $7.7M in FY2024.
• ·Stockholders’ equity grew to $81.3M as of Dec 31, 2025 from $15.1M.
• ·Net loss per common share improved to $(1.47) from $(4.89).